NEW YORK (GenomeWeb) – Cepheid announced today that it has received clearance from the US Food and Drug Administration for its Xpert MRSA NxG, a test for methicillin-resistant Staphylococcus aureus (MRSA) infection.

The test runs on the GeneXpert molecular diagnostic system and delivers results in around an hour, the company noted. To develop the test, Cepheid used an extensive library of MRSA strains collected around the world, and it included updated PCR primers and probes that detect both mecA and mecC strains, which reduces the frequency of false-positive results.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.